COVID-19 coagulopathy: from pathogenesis to treatment

T Alnima, MMG Mulder, BCT van Bussel… - Acta …, 2022‏ - karger.com
Abstract Coronavirus disease 2019 (COVID-19) has emerged as a pandemic at the end of
2019 and continues to exert an unfavorable worldwide health impact on a large proportion …

Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials

E Pilia, A Belletti, S Fresilli, G Finco… - Journal of Thrombosis and …, 2022‏ - Springer
Arterial and venous thrombotic events in COVID-19 cause significant morbidity and mortality
among patients. Although international guidelines agree on the need for anticoagulation, it …

[HTML][HTML] The role of heparin in COVID-19: An update after two years of pandemics

M Mangiafico, A Caff, L Costanzo - Journal of Clinical Medicine, 2022‏ - mdpi.com
Coronavirus disease 2019 (COVID-19) is associated with an increased risk of venous
thromboembolism (VTE) and coagulopathy, especially in critically ill patients. Endothelial …

[HTML][HTML] Venous thromboembolic disease in COVID-19, pathophysiology, therapy and prophylaxis

M Dybowska, D Wyrostkiewicz, L Opoka… - International journal of …, 2022‏ - mdpi.com
For over two years, the world has been facing the epidemiological and health challenge of
the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute …

COVID-19 patients with acute pulmonary embolism have a higher mortality risk: systematic review and meta-analysis based on Italian cohorts

M Zuin, G Rigatelli, C Bilato, L Quadretti… - Journal of …, 2022‏ - journals.lww.com
Background Acute pulmonary embolism has been recognized as a frequent complication of
COVID-19 infection influencing the clinical course and outcomes of these patients …

COVID-19 and cardiovascular disease in patients with chronic kidney disease

L Del Vecchio, O Balafa, E Dounousi… - Nephrology Dialysis …, 2024‏ - academic.oup.com
Millions of people worldwide have chronic kidney disease (CKD). Affected patients are at
high risk for cardiovascular (CV) disease for several reasons. Among various comorbidities …

The effect of heparin full-dose anticoagulation on survival of hospitalized, non-critically Ill COVID-19 patients: a meta-analysis of high quality studies

E Pilia, A Belletti, S Fresilli, TC Lee, A Zangrillo… - Lung, 2023‏ - Springer
Background International COVID-19 guidelines recommend thromboprophylaxis for non-
critically ill inpatients to prevent thrombotic complications. It is still debated whether full-dose …

Population pharmacokinetics and probability of target attainment analysis of nadroparin in different stages of COVID-19

P Piwowarczyk, M Szczukocka, W Cios… - Clinical …, 2023‏ - Springer
Abstract Background and Objective The risk of thrombotic complications in critical patients
with COVID-19 remains extremely high, and multicenter trials failed to prove a survival …

Continuation of therapeutic dose heparin for critically ill patients with COVID-19

CA Bradbury, PR Lawler, BJ McVerry… - Intensive Care …, 2023‏ - Springer
Randomized trials demonstrated improved clinical outcomes when therapeutic-dose
heparin is administered to non-critically ill patients hospitalized for coronavirus disease …

Anticoagulation in COVID-19 patients–An updated systematic review and meta-analysis

S Reis, A Faske, I Monsef, F Langer, OJ Müller… - Thrombosis …, 2024‏ - Elsevier
Background Thromboembolic events are common complications of COVID-19. Clinical study
results on safety and efficacy of anticoagulation in COVID-19 are controversial. Material and …